Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia

Blood

Volumn 115, Issue 14, 2010, Pages 2755-2762

  Zaja, Francesco ^a   Baccarani, Michele ^b   Mazza, Patrizio ^c   Bocchia, Monica ^d   Gugliotta, Luigi ^e   Zaccaria, Alfonso ^f   Vianelli, Nicola ^b   Defina, Marzia ^d   Tieghi, Alessia ^e   Amadori, Sergio ^g   Campagna, Selenia ^g   Ferrara, Felicetto ^h   Angelucci, Emanuele ⁱ   Usala, Emilio ⁱ   Cantoni, Silvia ^j   Visani, Giuseppe ^k   Fornaro, Antonella ^l   Rizzi, Rita ^m   De Stefano, Valerio ⁿ   Casulli, Francesco ^c   Battista, Marta Lisa ^a   Isola, Miriam ^o   Soldano, Franca ^o   Gamba, Enrica ^p   Fanin, Renato ^a   more..

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b L and A Seràgnoli Hematology and Oncological Sciences Institute   (Italy)

^c Ospedale Nord   (Italy)

^d UNIVERSITY HOSPITAL OF SIENA   (Italy)

^e S MARIA NUOVA HOSPITAL   (Italy)

^f SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^g UNIVERSITY OF ROME TOR VERGATA   (Italy)

^h CARDARELLI HOSPITAL   (Italy)

ⁱ Ospedale Oncologico A Businco   (Italy)

^j OSPEDALE NIGUARDA CA GRANDA   (Italy)

^k SAN SALVATORE HOSPITAL   (Italy)

^l SPIRITO SANTO HOSPITAL   (Italy)

^m POLICLINICO   (Italy)

ⁿ CATHOLIC UNIVERSITY   (Italy)

^o UNIVERSITY OF UDINE   (Italy)

^p NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN; RITUXIMAB;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BLEEDING; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE THROMBOCYTOPENIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEPHROLITHIASIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIB FRACTURE; SALVAGE THERAPY; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 77950974675     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-229815     Document Type: Article

References (38)

1. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999;94(3):909-913. (Pubitemid 29361821)
2. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3-40.
3. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104(9):2623-2634. (Pubitemid 39434940)
4. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet. 2008;371(9610):395-403.
5. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007(22):357:2237- 2247.
6. Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349(9):831-836. (Pubitemid 37025402)
7. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435-445. (Pubitemid 24030569)
8. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed lowgrade non-Hodgkin's lymphoma. Blood. 1997;90(6):2188-2195.
9. Chemnitz J, Draube A, Scheid C, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol. 2002;71(2):105-108.
10. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003;101(10):3827-3834. (Pubitemid 36857853)
11. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101(10):3857- 3861. (Pubitemid 36857857)
12. Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103(8):2925-2928. (Pubitemid 38451661)
13. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood. 2004; 103(12):4424-4428. (Pubitemid 38745966)
14. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-2581. (Pubitemid 38758544)
15. AhmedAR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355(17):1772-1779. (Pubitemid 44631360)
16. Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol. 2000;27(6 suppl 12):99-103. (Pubitemid 32164602)
17. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98(4):952-957.
18. Giagounidis AA, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol. 2002;69(2):95-100. (Pubitemid 35178108)
19. Braendstrup P, Pedersen M, Bjerrum OW. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with refractory idiopathic thrombocytopenic purpura [abstract]. Blood. 2003;102(suppl):298a.
20. Zaja F, Vianelli N, Sperotto A, et al. The B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica. 2003;88(5):538-546. (Pubitemid 36648443)
21. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125(2):232-239. (Pubitemid 38534976)
22. Zaja F, Vianelli N, Battista M, et al. Earlier administration of rituximab allows higher rate of long lasting reponse in adult patients with autoimmune thrombocytopenia. Exp Hematol. 2006;34(5):571-572.
23. Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG, Vela-Ojeda J. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Ann Hematol. 2007;86(12):871-877.
24. Mueller BU, Bennett CM, Feldman HA, et al. One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatr Blood Cancer. 2009;52(2):259-262.
25. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25-33. (Pubitemid 351650318)
26. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112(4):999-1004.
27. Shulman NR, Marder VJ, Weinrach RS. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura: physiologic, serologic and isotopic studies. Ann N Y Acad Sci. 1965;124(2):499-542.
28. van Leeuwen EF, van der Ven JT, Engelfriet CP, von dem Borne AE. Specificity of autoantibodies in autoimmune thrombocytopenia. Blood. 1982;59(19):23-26.
29. McMillan R, Wang L, Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost. 2003;1(3):485-491.
30. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110(8):2924-2930. (Pubitemid 350006946)
31. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell-depleting therapy with rituximab. Blood. 2008;112(4):1147-1150.
32. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.
33. Zaja F, Mazza P, Vianelli N, et al. A prospective randomized study of rituximab and dexamethasone vs dexamethasone alone in ITP [abstract]. Blood. 2007;110:567a.
34. Mazzucconi MG, Fazi P, Bernasconi S, et al. Thrombocytopenia Working Party. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007;109(4):1401-1407.
35. Bierling P, Godeau B. Intravenous immunoglobulin and autoimmune thrombocytopenic purpura: 22 years on. Vox Sang. 2004;86 81):8-14. (Pubitemid 38200450)
36. Medeot M, Zaja F, Vianelli N, et al. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: longterm follow-up results. Eur J Haematol. 2008;81(3):165-169.
37. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113(20):4834-4840.
38. Zaja F, Battista ML, Pirrotta MT, et al. Lower dose rituximab is active in adult patients with idiopathic thrombocytopenic purpura. Haematologica. 2008;93(6):930-933.